Short CV/Education and training

  • 1992
    Master of Science (Nutrition), Oregon State University, Corvallis

  • 1998
    Ph.D (Epidemiology) University of Washington, Seattle

Selected publications

  • Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. Journal of Clinical Oncology 2009: 27:3437-44.

  • Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, Potter JD, Ulrich CM. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 2011; 60:491-8.

  • Coghill AE, Newcomb PA, Poole EM, Hutter CM, Makar KW, Duggan D, Potter JD, Ulrich CM. Genetic variation in inflammatory pathways is related to colorectal cancer survival. Clin Cancer Res 2011;17:7139-47.

  • Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Reviews Cancer 2006;6:130-140, reprinted in Nature Reviews Cancer, Biomarkers Collection, 2007:S23-33.

  • Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, Campbell KL, Duggan C, Foster-Schubert KE, Kong A, Mason CE, Wang C-Y, Blackburn GL, Bain CE, Thompson HJ, McTiernan A, . Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 2012;72:2314-26.

  • Miller JW and Ulrich CM.. Folic acid and cancer -- where are we today? The Lancet. 25 January 2013 DOI: 10.1016/S0140-6736(13)60110-5.


Selected projects

  • The division of Preventive Oncology at the German Cancer Research Center reduces the burden of cancer by conducting cutting-edge research in three areas, (a) primary prevention (identification of risk factors and biologic mechanisms), (b) secondary prevention (early detection and screening), and tertiary prevention (improving clinical outcomes of cancer patients). Using state-of-the art methods, including coordinated -omic strategies in high quality observational and intervention studies, we explore molecular pathways of risk and clinical outcome. Targets are high-impact areas including energy balance/adipose-tissue/metabolic syndrome, inflammatory/immune-modulatory processes, and lifestyle/microbial communities. Pioneering work focuses on genetically-targeted, personalized prevention strategies through highly effective non-steroidal anti-inflammatory drugs. We collaborate closely with many colleagues at the Heidelberg University Clinic to define novel predictive and prognostic markers among cancer patients and to discern health behaviors with major impact on cancer prognosis. In uniquely designed clinical trials we test exercise as an adjuvant therapy in cancer and directly translate our findings into the clinic and population. Among other research initiatives, we lead the interdisciplinary ColoCare Study in Heidelberg as part of an international consortium with the Fred Hutchinson Cancer Research Center in Seattle and the Moffitt Cancer Center in Tampa. The study builds on a cohort of colorectal cancer patients and has as its main aim the improvement of prognosis among colorectal cancer patients through modifiable health behaviors as well as molecularly tailored therapies.

Membership in scientific bodies/juries

  • Member, Scientific Advisory Board, European Commission's ERA-NET on Translational Cancer Research (TRANSCAN), since 2011

  • Vice-Chair, Scientific Council, International Agency for Research on Cancer (IARC), since 2011

  • Elected Fellow, European Academy of Cancer Sciences, since 2011

  • Chair, Working Group Cancer Prevention, Early Detection and Outcomes, German Translational Consortium for Cancer Research, since 2010

  • Co-Chair, Working Group Prevention and Integrative Oncology (PRIO), Deutsche Krebsgesellschaft (German Cancer Society), since 2010

  • Chair, American Association of Cancer Research/Molecular Epidemiology (AACR/MEG), 2009 – 2010

  • Associate Editor "Cancer Research", 2006 – 2009

  • Editorial Board Member Cancer Epidemiology, Biomarkers & Prevention, since 2005

  • Session Chair, Speaker, and Program Committee Member on several AACR conferences, 2004 – 2012 including

  • Conference Chair and Session Chair, AACR/MEG Special Conference, Post-GWAS Horizons in Molecular Epidemiology: Digging Deeper into the Environment? Hollywood, Florida, November 2012

  • Co-Chairperson, Program Committee, 2010 AACR Annual Meeting, Washington DC

  • Conference Chair, AACR Special Conference Candidate Pathways, Whole Genome Scans: Reconciling Results, Looking Into the Future, Carefree, Arizona, May 2008

  • Conference Co-Chair and Session Chair, TREC-AACR Special Conference Energy Balance and Cancer Risk: Markers and Mediators, Lansdowne, Virginia, February 2008

  • Program Committee Member, AACR Special Conference The Future of Molecular Epidemiology: New Tools, Biomarkers, and Opportunities, Miami, Florida, June 2010

  • Grant Reviewer on several NIH study sections, including the 2010 NIH Directors New Innovator Award, 2004 – 2010

  • Fulbright Scholarship and Fulbright Professional Enhancement Grant, 1991 – 1993

Contact

You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here

Testimonials

  1. Read what our members say about AcademiaNet.

No more excuses!

  1. Please download the brochure "No more excuses" and read more about female experts in Europe, and about AcademiaNet.

Similar profiles

  1. Prof. Anne Angelillo-Scherrer

    Biological and related sciences , HealthInternal medicine, Hematology - hemostasis, Clinical laboratory sciences - hematology

  2. Prof. Dr. Myriam Aouadi

    HealthObesity, Diabetes, Immunology

  3. Dr. Nicola Allen

    HealthRole of astrocytes in brain function

  4. Prof. Dr. Heike Allgayer

    Biological and related sciences , Health